No Picture
News

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today an… […]

No Picture
News

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Aug. 21, 2020 /PRNewswire/ — Inhibrx, Inc. (“Inhibrx”) (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the closing of its previously … […]

No Picture
News

Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CARLSBAD, Calif., Aug. 4, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, wit… […]

No Picture
News

Qualigen Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CARLSBAD, Calif., Aug. 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $1… […]

No Picture
News

Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CARLSBAD, Calif., July 10, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, wi… […]